Compare ZURA & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZURA | CGC |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | Canada |
| Employees | 30 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.8M | 404.3M |
| IPO Year | N/A | 2023 |
| Metric | ZURA | CGC |
|---|---|---|
| Price | $5.54 | $1.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | 601.3K | ★ 8.2M |
| Earning Date | 05-07-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,759,000.00 |
| Revenue This Year | N/A | $8.04 |
| Revenue Next Year | N/A | $11.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $0.84 |
| 52 Week High | $7.25 | $2.38 |
| Indicator | ZURA | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 64.19 |
| Support Level | $5.35 | $1.13 |
| Resistance Level | $5.75 | $1.25 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 12.50 | 92.07 |
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.